|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
59,420,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Generation Bio is a genetic medicines company providing durable, redosable treatments for potentially various of patients living with rare and prevalent diseases. Co.'s non-viral genetic medicine platform incorporates its DNA construct called closed-ended DNA; its cell-targeted lipid nanoparticle delivery system; and its capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, to produce ceDNA. Using Co.'s platform, it is developing genetic medicines to provide targeted delivery of genetic payloads that include large and multiple genes to a range of cell types across a range of diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
551,455 |
642,217 |
Total Buy Value |
$0 |
$0 |
$778,895 |
$1,265,385 |
Total People Bought |
0 |
0 |
4 |
4 |
Total Buy Transactions |
0 |
0 |
7 |
12 |
Total Shares Sold |
6,719 |
6,719 |
14,725 |
34,618 |
Total Sell Value |
$18,410 |
$18,410 |
$41,694 |
$143,993 |
Total People Sold |
1 |
1 |
2 |
2 |
Total Sell Transactions |
1 |
1 |
4 |
11 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mcdonough Geoff |
PRESIDENT AND CEO |
|
2021-04-23 |
4 |
AS |
$35.10 |
$351,000 |
D/D |
(10,000) |
1,184,080 |
|
- |
|
Zimmermann Tracy |
CHIEF DEVELOPMENT OFFICER |
|
2021-04-22 |
4 |
AS |
$33.32 |
$83,300 |
D/D |
(2,500) |
0 |
|
- |
|
Zimmermann Tracy |
CHIEF DEVELOPMENT OFFICER |
|
2021-04-22 |
4 |
OE |
$4.59 |
$11,475 |
D/D |
2,500 |
2,500 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-22 |
4 |
AS |
$34.03 |
$51,045 |
D/D |
(1,500) |
198,154 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-22 |
4 |
OE |
$0.60 |
$900 |
D/D |
1,500 |
199,654 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-21 |
4 |
AS |
$31.07 |
$46,605 |
D/D |
(1,500) |
198,154 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-21 |
4 |
OE |
$0.60 |
$900 |
D/D |
1,500 |
199,654 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-16 |
4 |
AS |
$28.03 |
$42,045 |
D/D |
(1,500) |
198,154 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-16 |
4 |
OE |
$0.60 |
$900 |
D/D |
1,500 |
199,654 |
|
- |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2021-04-14 |
4 |
AS |
$26.40 |
$622,995 |
D/D |
(23,413) |
0 |
|
- |
|
Rhodes Jason P |
Director |
|
2021-04-14 |
4 |
AS |
$26.40 |
$622,995 |
I/I |
(23,413) |
0 |
|
- |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2021-04-13 |
4 |
AS |
$25.09 |
$1,085,744 |
D/D |
(43,145) |
23,413 |
|
- |
|
Rhodes Jason P |
Director |
|
2021-04-13 |
4 |
AS |
$25.09 |
$1,085,744 |
I/I |
(43,145) |
23,413 |
|
- |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2021-04-12 |
4 |
AS |
$26.07 |
$1,938,229 |
D/D |
(74,124) |
66,558 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-12 |
4 |
AS |
$26.12 |
$157,446 |
D/D |
(6,000) |
198,154 |
|
- |
|
Stanton Matthew |
CHIEF SCIENTIFIC OFFICER |
|
2021-04-12 |
4 |
OE |
$0.60 |
$3,600 |
D/D |
6,000 |
204,154 |
|
- |
|
Rhodes Jason P |
Director |
|
2021-04-12 |
4 |
AS |
$26.07 |
$1,938,229 |
I/I |
(74,124) |
66,558 |
|
- |
|
Rhodes Jason P |
Director |
|
2021-04-09 |
4 |
AS |
$27.57 |
$1,205,948 |
I/I |
(43,681) |
140,682 |
|
- |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2021-04-09 |
4 |
AS |
$27.57 |
$1,205,948 |
D/D |
(43,681) |
140,682 |
|
- |
|
Rhodes Jason P |
Director |
|
2021-04-08 |
4 |
AS |
$28.47 |
$1,241,241 |
I/I |
(43,550) |
184,363 |
|
- |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2021-04-08 |
4 |
AS |
$28.47 |
$1,241,241 |
D/D |
(43,550) |
184,363 |
|
- |
|
Rhodes Jason P |
Director |
|
2021-04-07 |
4 |
AS |
$28.48 |
$1,136,671 |
I/I |
(39,864) |
227,913 |
|
- |
|
Atlas Venture Associates X, Llc |
10% Owner |
|
2021-04-07 |
4 |
AS |
$28.48 |
$1,136,671 |
D/D |
(39,864) |
227,913 |
|
- |
|
Kerr Douglas |
CHIEF MEDICAL OFFICER |
|
2021-04-05 |
4 |
AS |
$29.91 |
$423,451 |
D/D |
(14,072) |
326,558 |
|
- |
|
Kerr Douglas |
CHIEF MEDICAL OFFICER |
|
2021-04-05 |
4 |
OE |
$5.16 |
$72,612 |
D/D |
14,072 |
340,630 |
|
- |
|
294 Records found
|
|
Page 9 of 12 |
|
|